| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159498 | BDSI | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
Oct, 2016
(7 years ago) | |
| US7579019 | BDSI | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
Jan, 2020
(4 years ago) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(8 years from now) | |
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(11 years from now) | |
Bunavail is owned by Bdsi.
Bunavail contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Bunavail has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bunavail are:
- US6159498
- US7579019
Bunavail was authorised for market use on 06 June, 2014.
Bunavail is available in film;buccal dosage forms.
Bunavail can be used as treatment of opioid dependence, maintenance treatment of opioid dependence.
The generics of Bunavail are possible to be released after 24 April, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 06, 2017 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
BUNAVAIL family patents
